Expression of lysyl oxidase in human osteosarcoma and its clinical significance: A tumor suppressive role of LOX in human osteosarcoma cells

International Journal of Oncology

Volumn 43, Issue 5, 2013, Pages 1578-1586

  Xu, Xin ^a   Wang, Bin ^a   Xu, Yanling ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Growth; Lysyl oxidase; Migration; OPsteosarcoma; PI3K

Indexed keywords

3 AMINOPROPIONITRILE; ADENOVIRUS VECTOR; CYCLINE; GELATINASE A; GELATINASE B; KI 67 ANTIGEN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN KINASE B; PROTEIN LYSINE 6 OXIDASE;

ADENOVIRUS; ADULT; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; APOPTOSIS; BLOTTING, WESTERN; BONE AND BONES; BONE NEOPLASMS; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; OSTEOSARCOMA; PROGNOSIS; PROTEIN-LYSINE 6-OXIDASE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; WOUND HEALING; YOUNG ADULT;

EID: 84885061871     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2067     Document Type: Article

References (39)

1. Thompson L, Wang S, Tawfik O, et al: Effect of 25-hydroxyvitamin D3 and 1 α,25 dihydroxyvitamin D3 on differentiation and apoptosis of human osteosarcoma cell lines. J Orthop Res 30: 831-844, 2012.
2. Chugh R: Experimental therapies and clinical trials in bone sarcoma. J Natl Compr Canc Netw 8: 715-725, 2010.
3. Dai X, Ma W, He X, et al: Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Med Sci Monit 17: RA177-190, 2011.
4. Kagan HM and Trackman PC: Properties and function of lysyl oxidase. Am J Respir Cell Mol Biol 5: 206-210, 1991.
5. Kim YM, Kim EC and Kim Y: The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin. Mol Biol Rep 38: 145-149, 2011.
6. Bais MV, Nugent MA, Stephens DN, et al: Recombinant lysyl oxidase propeptide protein inhibits growth and promotes apoptosis of pre-existing murine breast cancer xenografts. PLoS One 7: e31188, 2012.
7. Palamakumbura AH, Vora SR, Nugent MA, et al: Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling. Oncogene 28: 3390-3400, 2009.
8. Hurtado PA, Vora S, Sume SS, et al: Lysyl oxidase propeptide inhibits smooth muscle cell signaling and proliferation. Biochem Biophys Res Commun 366: 156-161, 2008.
9. Erler JT, Bennewith KL, Nicolau M, et al: Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440: 1222-1226, 2006.
10. Kirschmann DA, Seftor EA, Fong SF, et al: A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res 62: 4478-4483, 2002.
11. Baker AM, Bird D, Lang G, et al: Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK. Oncogene 73: 583-594, 2013.
12. Lapointe J, Li C, Higgins JP, et al: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101: 811-816, 2004.
13. Wu J, Cai C, Tong D, et al: Lysyl oxidase G473A polymorphism is associated with increased risk of ovarian cancer. Genet Test Mol Biomarkers 16: 915-919, 2012.
14. Stassar MJ, Devitt G, Brosius M, et al: Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. Br J Cancer 85: 1372-1382, 2001.
15. Giampuzzi M, Botti G, Cilli M, et al: Down-regulation of lysyl oxidase-induced tumorigenic transformation in NRK-49F cells characterized by constitutive activation of ras proto-oncogene. J Biol Chem 276: 29226-29232, 2001.
16. Bouez C, Reynaud C, Noblesse E, et al: The lysyl oxidase LOX is absent in basal and squamous cell carcinomas and its knockdown induces an invading phenotype in a skin equivalent model. Clin Cancer Res 12: 1463-1469, 2006.
17. Barker HE, Cox TR and Erler JT: The rationale for targeting the LOX family in cancer. Nat Rev Cancer 12: 540-552, 2012.
18. Novello C, Pazzaglia L, Cingolani C, et al: miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol 42: 667-675, 2013.
19. Sollazzo MR, Benassi MS, Magagnoli G, et al: Increased c-myc oncogene expression in Ewing's sarcoma: correlation with Ki67 proliferation index. Tumori 85: 167-173, 1999.
20. Li B, Yang Y, Jiang S, et al: Adenovirus-mediated overexpression of BMP-9 inhibits human osteosarcoma cell growth and migration through downregulation of the PI3K/AKT pathway. Int J Oncol 41: 1809-1819, 2012.
21. Liu ZL, Wang G, Peng AF, et al: Fatty acid synthase expression in osteosarcoma and its correlation with pulmonary metastasis. Oncol Lett 4: 878-882, 2012.
22. Kamei S, Sakayama K, Tamashiro S, et al: Ketoprofen in topical formulation decreases the matrix metalloproteinase-2 expression and pulmonary metastatic incidence in nude mice with osteosarcoma. J Orthop Res 27: 909-915, 2009.
23. Duan DP, Dang XQ, Wang KZ, et al: The cyclooxygenase-2 inhibitor NS-398 inhibits proliferation and induces apoptosis in human osteosarcoma cells via downregulation of the survivin pathway. Oncol Rep 28: 1693-1700, 2012.
24. Korpi JT, Hagstrom J, Lehtonen N, et al: Expression of matrix metalloproteinases-2, -8, -13, -26, and tissue inhibitors of metalloproteinase-1 in human osteosarcoma. Surg Oncol 20: e18-e22, 2011.
25. Zhang Y, Song L, Cai L, et al: Effects of baicalein on apoptosis, cell cycle arrest, migration and invasion of osteosarcoma cells. Food Chem Toxicol 53C: 325-333, 2012.
26. Rasmussen N and Rathmell WK: Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug development. Curr Clin Pharmacol 6: 199-206, 2011.
27. Kubista B, Klinglmueller F, Bilban M, et al: Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma. Int Orthop 35: 401-411, 2011.
28. Buchinger B, Spitzer S, Karlic H, et al: Lysyl oxidase (LOX) mRNA expression and genes of the differentiated osteoblastic phenotype are upregulated in human osteosarcoma cells by suramin. Cancer Lett 265: 45-54, 2008.
29. Payne SL, Fogelgren B, Hess AR, et al: Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res 65: 11429-11436, 2005.
30. Gacheru SN, Thomas KM, Murray SA, et al: Transcriptional and post-transcriptional control of lysyl oxidase expression in vascular smooth muscle cells: effects of TGF-beta 1 and serum deprivation. J Cell Biochem 65: 395-407, 1997.
31. Peinado H, Moreno-Bueno G, Hardisson D, et al: Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas. Cancer Res 68: 4541-4550, 2008.
32. Yu Z, Sato S, Trackman PC, et al: Blimp1 activation by AP-1 in human lung cancer cells promotes a migratory phenotype and is inhibited by the lysyl oxidase propeptide. PLoS One 7: e33287, 2012.
33. Palamakumbura AH, Jeay S, Guo Y, et al: The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells. J Biol Chem 279: 40593-40600, 2004.
34. Hotfilder M, Sondermann P, Senss A, et al: PI3K/AKT is involved in mediating survival signals that rescue Ewing tumour cells from fibroblast growth factor 2-induced cell death. Br J Cancer 92: 705-710, 2005.
35. Liu B, Shi ZL, Feng J, et al: Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt. Cell Biol Int 32: 494-501, 2008.
36. Jin S, Pang RP, Shen JN, et al: Grifolin induces apoptosis via inhibition of PI3K/AKT signalling pathway in human osteosarcoma cells. Apoptosis 12: 1317-1326, 2007.
37. Jeay S, Pianetti S, Kagan HM, et al: Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B. Mol Cell Biol 23: 2251-2263, 2003.
38. Pez F, Dayan F, Durivault J, et al: The HIF-1-inducible lysyl oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell growth. Cancer Res 71: 1647-1657, 2011.
39. Voloshenyuk TG, Landesman ES, Khoutorova E, et al: Induction of cardiac fibroblast lysyl oxidase by TGF-beta1 requires PI3K/Akt, Smad3, and MAPK signaling. Cytokine 55: 90-97, 2011.